GSK said on Monday its cancer drug Jemperli along with chemotherapy and followed by Zejula and Jemperli as a maintenance therapy met the primary goal of progression-free survival in patients with advanced or recurrent endometrial cancer in a late-stage trial.
The British company said the trial met the primary goal with a "statistically significant and clinically meaningful" benefit observed in both the overall patient population and in a subpopulation of patients with certain types of tumours.
https://news.yahoo.com/gsks-cancer-drug-combination-meets-074931072.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.